GeneDx Holdings Corp (NASDAQ:WGS)’s traded shares stood at 7.61 million during the last session, with the company’s beta value hitting 1.95. At the close of trading, the stock’s price was $66.85, to imply a decrease of -42.85% or -$50.12 in intraday trading. The WGS share’s 52-week high remains $117.75, putting it -76.14% down since that peak but still an impressive 79.21% since price per share fell to its 52-week low of $13.90. The company has a valuation of $1.91B, with an average of 1.6 million shares in intraday trading volume over the past 10 days and average of 1.05 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for GeneDx Holdings Corp (WGS), translating to a mean rating of 2.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give WGS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.1.
GeneDx Holdings Corp (NASDAQ:WGS) trade information
After registering a -42.85% downside in the last session, GeneDx Holdings Corp (WGS) has traded red over the past five days. The 5-day price performance for the stock is -36.75%, and -24.52% over 30 days. With these gigs, the year-to-date price performance is -13.02%. Short interest in GeneDx Holdings Corp (NASDAQ:WGS) saw shorts transact 3.25 million shares and set a 4.33 days time to cover.
The extremes give us $21 and $70 for target low and target high price respectively. As such, WGS has been trading -4.71% off suggested target high and 68.59% from its likely low.
GeneDx Holdings Corp (WGS) estimates and forecasts
The rating firms project that company’s revenue will grow 19.33% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 85.62M. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 93.3M.Earnings reports from the last fiscal year show that sales brought in 70.51M and 76.87M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 21.42% before jumping 21.37% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 96.65% for the past 5-year period. While 2025 is set for a 277.81% return in earnings, projections for the next 5 years are at 121.82% annually.
WGS Dividends
GeneDx Holdings Corp has its next earnings report out on 2025-Feb-17. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
GeneDx Holdings Corp (NASDAQ:WGS)’s Major holders
GeneDx Holdings Corp insiders hold 12.70% of total outstanding shares, with institutional holders owning 86.81% of the shares at 99.44% float percentage. In total, 86.81% institutions holds shares in the company, led by CASDIN CAPITAL, LLC. As of 2024-06-30, the company held over 3.53 million shares (or 13.2482% of shares), all amounting to roughly $92.18 million.
The next major institution holding the largest number of shares is CORVEX MANAGEMENT LP with 2.47 million shares, or about 9.2937% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $64.66 million.
We also have Fidelity Securities Fund-Fidelity Blue Chip Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the GeneDx Holdings Corp (WGS) shares. Going by data provided on Feb 28, 2025 , Fidelity Securities Fund-Fidelity Blue Chip Growth Fund holds roughly 717.8 shares. This is just over 2.56% of the total shares, with a market valuation of $47.98 million. Data from the same date shows that the other fund manager holds a little less at 521.12, or 1.86% of the shares, all valued at about 34.84 million.
